Misplaced Pages

Darbinurad

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.

This is an old revision of this page, as edited by Boghog (talk | contribs) at 03:56, 2 January 2025 (created drug stub). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Revision as of 03:56, 2 January 2025 by Boghog (talk | contribs) (created drug stub)(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff)

Pharmaceutical compound
Darbinurad
Clinical data
Other namesD-0120
Identifiers
IUPAC name
  • 2-sulfanylmethyl]cyclopropyl]acetic acid
CAS Number
PubChem CID
UNII
Chemical and physical data
FormulaC18H16N2O2S
Molar mass324.40 g·mol
3D model (JSmol)
SMILES
  • C1CC1(CC(=O)O)CSC2=C(C=NC=C2)C3=CC=C(C=C3)C#N
InChI
  • InChI=InChI=1S/C18H16N2O2S/c19-10-13-1-3-14(4-2-13)15-11-20-8-5-16(15)23-12-18(6-7-18)9-17(21)22/h1-5,8,11H,6-7,9,12H2,(H,21,22)
  • Key:RHASGUGQMCVYMQ-UHFFFAOYSA-N

Darbinurad is a investigational new drug that is being evaluated for the treatment of gout. It is a selective urate transporter 1 (URAT1) inhibitor that blocks the reabsorption of uric acid within the renal proximal tubule, thereby reducing serum uric acid concentrations.

References

  1. Kaufmann D, Chaiyakunapruk N, Schlesinger N (November 2024). "Optimizing gout treatment: A comprehensive review of current and emerging uricosurics". Joint Bone Spine. 92 (2): 105826. doi:10.1016/j.jbspin.2024.105826. PMID 39622367.
  2. "Darbinurad". PatSnap.
Stub icon

This pharmacology-related article is a stub. You can help Misplaced Pages by expanding it.

Categories: